{"title":"The Study Design","authors":"R. Palm, M. Hodgson, R. Blanchard, D. Lyons","doi":"10.4324/9780429045790-4","DOIUrl":null,"url":null,"abstract":"1Centocor Research & Development, a Division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, United States; 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria; 3Brigham and Women's Hospital, Boston, United States Results from a Two-part, Proof-of-concept, Dose-ranging, Multicenter, International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Of Sirukumab, a Human Anti-interleukin-6 Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy Disclosures","PeriodicalId":160962,"journal":{"name":"Earthquake Insurance in California","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Earthquake Insurance in California","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4324/9780429045790-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
1Centocor Research & Development, a Division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, United States; 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria; 3Brigham and Women's Hospital, Boston, United States Results from a Two-part, Proof-of-concept, Dose-ranging, Multicenter, International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Of Sirukumab, a Human Anti-interleukin-6 Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy Disclosures
1Centocor Research & Development, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Malvern，美国分部;2维也纳医科大学和Hietzing医院，奥地利维也纳;一项两部分、概念验证、剂量范围、多中心、国际、随机、双盲、安慰剂对照的人类抗白细胞介素-6单克隆抗体Sirukumab在类风湿关节炎患者中的2期研究结果，尽管有甲氨蝶呤治疗的披露
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
